Skip to main content
European Commission logo print header

The Development of Immunotherapeutic Strategies to Treat Haematological and Neoplastic diseases on the Basis of Optimised Allogeneic Stem Cell Transplantation

Objectif

Haematological disease, either malignant or otherwise, carries a significant burden of morbidity and mortality. Recent advances in mapping and sequencing of the human genome make possible an approach to the treatment of these diseases which exploits the genetic differences between individuals to produce targets through which the immune system can eliminate the diseased cells. In practice this process of immunotherapy involves an allogeneic haematopoietic stem cell transplant, with subsequent delivery of specific immune effector cells expanded from the donor. The AlloStem project brings together clinical and research groups from across the EU who individually is amongst the world leaders in the field of immunotherapy to coordinate and complement their efforts into a unified and directed program. We will develop new protocols for the treatment of patients with haematological disease and for the effective delivery of immunogenomics-based therapies. The end results of the project will be both an improvement in the health care for EU citizens and the development of new genome-based pharmaceuticals that can be exploited worldwide.

Mots‑clés

Appel à propositions

FP6-2002-LIFESCIHEALTH
Voir d’autres projets de cet appel

Régime de financement

IP - Integrated Project

Coordinateur

THE ANTHONY NOLAN TRUST
Contribution de l’UE
Aucune donnée
Adresse
The Royal Free Hospital, Pond Street, Hampstead
LONDON
Royaume-Uni

Voir sur la carte

Liens
Coût total
Aucune donnée

Participants (28)